As a result of the EOP2 meeting, Cassava Sciences believes its clinical program for simufilam is green-lighted to commence a large, Phase 3 clinical program in patients with Alzheimer’s disease, pending official FDA meeting minutes of the EOP2 meeting.
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-announces-significant-program-progress-and